West Pharmaceutical Services: Q2 Earnings Insights

Shares of West Pharmaceutical Services WST were flat in pre-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share rose 40.45% year over year to $1.25, which beat the estimate of $0.88.

Revenue of $527,200,000 up by 12.24% year over year, which beat the estimate of $490,580,000.

Outlook

The upcoming fiscal year's EPS expected to be between $4.15 and $4.25.

The upcoming fiscal year's revenue expected to be between $2,035,000,000 and $2,055,000,000.

Details Of The Call

Date: Jul 23, 2020

Time: 09:00 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/fjvys8u9

Technicals

Company's 52-week high was at $257.92

52-week low: $120.12

Price action over last quarter: Up 30.60%

Company Description

West Pharmaceutical Services is a Pennsylvania-based medical supplies company that operates as a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West develops, manufactures, and distributes elastomer-based supplies for the containment and administration of injectable drugs, including basic equipment such as syringes, stoppers, and plungers, along with somewhat more complicated devices including auto-injectors and other self-injection platforms. The company reports in two segments: proprietary products (75% of 2019 sales) and contract-manufactured products (25%). The firm generates 56% of its revenue from international markets and 44% from the United States.